GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PHAXIAM Therapeutics SA (XPAR:PHXM) » Definitions » Other Gross PPE

PHAXIAM Therapeutics (XPAR:PHXM) Other Gross PPE : €0.00 Mil (As of Sep. 2023)


View and export this data going back to 2013. Start your Free Trial

What is PHAXIAM Therapeutics Other Gross PPE?

PHAXIAM Therapeutics's Other Gross PPE for the quarter that ended in Sep. 2023 was €0.00 Mil.

PHAXIAM Therapeutics's quarterly Other Gross PPE declined from Dec. 2022 (€2.91 Mil) to Jun. 2023 (€0.00 Mil) but then stayed the same from Jun. 2023 (€0.00 Mil) to Sep. 2023 (€0.00 Mil).

PHAXIAM Therapeutics's annual Other Gross PPE increased from Dec. 2020 (€20.70 Mil) to Dec. 2021 (€22.09 Mil) but then declined from Dec. 2021 (€22.09 Mil) to Dec. 2022 (€2.91 Mil).

PHAXIAM Therapeutics Other Gross PPE Historical Data

The historical data trend for PHAXIAM Therapeutics's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PHAXIAM Therapeutics Other Gross PPE Chart

PHAXIAM Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.01 22.39 20.70 22.09 2.91

PHAXIAM Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.92 - 2.91 - -

PHAXIAM Therapeutics Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

PHAXIAM Therapeutics (XPAR:PHXM) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PHAXIAM Therapeutics SA (XPAR:PHXM) » Definitions » Other Gross PPE
Comparable Companies
XPAR:ALVIO XPAR:GNRO XPAR:ALGEN XPAR:ALDVI XPAR:SIGHT XPAR:ALCOX XPAR:ABNX XPAR:POXEL XPAR:FALG XPAR:ALHYG OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
PHXM:USA 2E41:Germany
Address
60 Avenue Rockefeller, Lyon, FRA, 69008
Website
https://www.erytech.com
Erytech Pharma SA is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Its ERYCAPS platform, uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its lead product candidate eryaspase, also referred as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing eryaspase for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple negative breast cancer, or TNBC.